Close Menu

Companion Diagnostics

News on companion diagnostics and drug/test co-development.

The companies began working together in 2018, when MEDx was known as Qiagen Translational Medicine, on companion and in vitro diagnostics.

Personalis plans to develop a companion diagnostic to MapKure's BRAF inhibitor, BGB-3245, once biomarkers have been identified in the study.

The company is focused on developing and commercializing therapeutic and companion diagnostic products to treat inflammatory bowel disease.

The new service, slated for launch in the second half of 2021, will allow Myriad to expand its cancer tumor profiling services.

The partners will develop a test to identify women most likely to benefit from VGX-3100, Inovio's immunotherapy to treat HPV-associated advanced cervical dysplasia.

May
13
Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.